Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) EBITDA (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed EBITDA for 4 consecutive years, with -$11.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 52.88% to -$11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$36.5 million through Dec 2025, up 31.15% year-over-year, with the annual reading at -$36.5 million for FY2025, 31.15% up from the prior year.
  • EBITDA for Q4 2025 was -$11.1 million at Spruce Biosciences, down from -$8.2 million in the prior quarter.
  • The five-year high for EBITDA was -$2.7 million in Q2 2025, with the low at -$23.6 million in Q4 2024.
  • Average EBITDA over 4 years is -$11.5 million, with a median of -$11.5 million recorded in 2022.
  • The sharpest move saw EBITDA plummeted 136.85% in 2024, then surged 70.68% in 2025.
  • Over 4 years, EBITDA stood at -$10.8 million in 2022, then grew by 8.14% to -$9.9 million in 2023, then plummeted by 136.85% to -$23.6 million in 2024, then surged by 52.88% to -$11.1 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$11.1 million, -$8.2 million, and -$2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.